Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version in early 2025 Charlotte Phillipp is a Weekend Writer-Reporter at ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound. The medicine, part of the class known as GLP-1 ...

On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss ... versions of semaglutide, the chemical name for Wegovy, and said the agency ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

Sleep apnea causes people to stop and start breathing repeatedly Zepbound is first drug approved by FDA to help treat it Two studies found that those who used it saw reduction in apnea events ...

many cases of sleep apnea are related to other factors such as the structure of the jaw and upper airway," the group said in ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking the ...